ErbB2:EGFR ratio is a critical predictor of a mitogenic response to EGF in a prostate cancer model - potential implications for the use of anti-ErbB2 or dual tyrosine kinase inhibitors

Research output: Contribution to journalArticle

Authors

Details

Original languageEnglish
Pages (from-to)846-853
Number of pages8
JournalNeoplasia
Volume6
Publication statusPublished - 1 Nov 2004